Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT

  • End date
    Dec 10, 2024
  • participants needed
  • sponsor
    Karolinska Institutet
Updated on 10 September 2021


Open label study with peanut oral immunotherapy (OIT). Peanut allergic children aged >1 and <4 years of age will be randomized 2:1 to:

  1. Peanut OIT with slow up-dosing (40-60 weeks) up to a maintenance dose of 286 mg daily oral peanut protein and
  2. Control group with peanut allergic children who do not undergo OIT.
  3. In addition, a group of healthy children without allergic diseases will be included in the study.

The primary outcome, sustained unresponsiveness (i.e. tolerance) to 600 mg peanut protein after 3 years of OIT, efficacy and safety will be compared between group 1 and 2. Group 3 is a control group for analyses of immunological markers.


Problem: Today there is no clinically available treatment for peanut allergy. Oral Immunotherapy (OIT) studies have shown promising results, particularly in younger children (<4 years).

Intervention: Peanut OIT in children aged >1 and <4 years with peanut allergy (clinical symptoms at peanut challenge and IgE >0.1 kU /l to peanut and/or Ara h 2).

Comparison: Three groups are compared. Peanut allergic children are randomized 2:1 to group 1 (active OIT) or group 2 (control). Group 3 consists of age-matched healthy controls:

Group 1; Children with peanut allergy receiving peanut OIT, slow up-dosing, 40-60 weeks, until the maintenance dose 286 mg peanut protein. Three years' treatment.

Group 2; Age-matched children with peanut allergy who do not undergo OIT peanut. Peanut challenge one and three years after inclusion.

Group 3; Healthy, non-allergic, age-matched children. No challenges are performed in this group.

Inclusion of study subjects: A review of samples sent to the Karolinska University Laboratory for IgE-ab responses to peanut/Ara h 2 for children in the Stockholm area aged 1-<4 years is used for identification of potential participants to whom a letter is sent with information about the study. The families are randomized 2:1 to OIT or control group, group 1 or group 2. Children without allergies, healthy Controls (group 3), will be identified through the day surgery at Astrid Lindgren's Children's Hospital.

Outcomes: The primary outcome is defined as sustained unresponsiveness to 775 mg peanut protein (cumulative dose) at an open oral peanut challenge 4 weeks after 3 years of OIT was stopped (group 1 and 2).

Secondary outcomes are adverse events among peanut allergic children with/without OIT treatment (group 1 and 2), and changes in quality of life parameters and immunological markers (group, 1, 2, 3).

Condition peanut allergy, allergy to peanuts
Treatment Peanut (bamba)
Clinical Study IdentifierNCT04511494
SponsorKarolinska Institutet
Last Modified on10 September 2021


Yes No Not Sure

Inclusion Criteria

Children 1 - <4 years old at inclusion
Positive baseline challenge at a maximum of the 250 mg peanut protein-dose with at least one objective symptom, or positive peanut challenge performed in the clinic in a similar way within 1 year from study start
IgE-ab to peanut and/or Ara h 2 0.1 kUA/l, analyzed within 12 months from start of study
Written consent for participation in the study from both Guardians

Exclusion Criteria

Other serious illness
Previously life-threatening anaphylaxis (intensive care), regardless of the triggering agent
A history of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, severe chronic gastroesophageal reflux disease (GERD), symptoms of dysphagia, unclear recurrent GI disorders
Participation in another intervention study, if included in intervention Group
Severe uncontrolled asthma
Ongoing medication with biological drugs or oral steroids
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note